NASDAQ:PZRX

PhaseRx (PZRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.28
$0.34
50-Day Range
$0.28
$0.28
52-Week Range
$0.22
$1.95
Volume
1.05 million shs
Average Volume
1.24 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About PhaseRx

PhaseRx, Inc. operates as a biopharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. Its product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency; argininosuccinate lyase deficiency; and argininosuccinate synthetase deficiency. The company was founded by Robert W. Overell, Patrick S. Stayton, Allan S. Hoffman, Oliver W. Press, and Paul H. Johnson on March 9, 2006 and is headquartered in Seattle, WA.

PZRX Stock News Headlines

Powszechny Zaklad Ubezpieczen SA PZU
Nimbus Group AB (BOAT)
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
PhaseRx (PZRXQ) Earnings Dates & Reports
Tongwei Co Ltd (600438)
DeNA Co Ltd (2432)
See More Headlines
Receive PZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2017
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PZRX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Steven H. Gillis Ph.D. (Age 63)
    Independent Chairman of the Board
  • Robert W. Overell Ph.D. (Age 61)
    President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director
  • Sean Monahan Ph.D.
    Vice President - Chemistry
  • Mary G. Prieve Ph.D.
    Vice President - Biology
  • Gordon Brandt M.D. (Age 57)
    Chief Medical Officer
  • James D. Watson
    Head of Corporate Development
  • Paul H. Johnson Ph.D. (Age 73)
    Director
  • Brian G. Atwood (Age 64)
    Independent Director
  • Michelle Renee Griffin (Age 51)
    Independent Director
  • Peggy V. Phillips (Age 63)
    Independent Director

PZRX Stock Analysis - Frequently Asked Questions

How were PhaseRx's earnings last quarter?

PhaseRx, Inc. (NASDAQ:PZRX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.14.

What other stocks do shareholders of PhaseRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseRx investors own include Avid Bioservices (CDMO), Immutep (IMMP), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Eleven Biotherapeutics (EBIO), Net Element (NETE), OHR Pharmaceutical (OHRP),

When did PhaseRx IPO?

PhaseRx (PZRX) raised $18 million in an IPO on Wednesday, May 18th 2016. The company issued 3,700,000 shares at a price of $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners served as the underwriters for the IPO.

This page (NASDAQ:PZRX) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners